Associated tags: Omega, Medicine, Pharmaceutical industry, Patient, Therapy, Medtech, Renal artery, Blood pressure, Stroke, Kidney failure, Hypertension, Physician, Wiśniewski, The Company, Axon Sports, Drug discovery, TEL
Locations: GERMANY, MASSACHUSETTS, SWITZERLAND, FRANKREICH, PARIS, ISRAEL, FRANCE, ITALY, NORWAY, ENGLAND, LONDON, EUROPE, OSLO, UNITED STATES, NORTH AMERICA, RARE
Retrieved on:
Thursday, January 4, 2024
Professional Services,
Finance,
Merck Group,
Omega,
CAIA,
BBA,
Therapy,
FRM,
University,
IPO,
Patient,
CFA,
Management Omega Funds , a leading international healthcare venture capital firm focused on delivering impactful medicines to patients, is pleased to announce the promotion of Francesco Draetta to Managing Director.
Key Points:
- Omega Funds , a leading international healthcare venture capital firm focused on delivering impactful medicines to patients, is pleased to announce the promotion of Francesco Draetta to Managing Director.
- He also co-leads the Firm’s fundraising efforts, which resulted in more than $1.1 billion raised across Omega Fund VI and Omega Fund VII.
- “Francesco has been instrumental to Omega’s growth, particularly across our investment and fundraising activities," said Omega Founder and Managing Director Otello Stampacchia.
- “We look forward to his continued success as he assumes his new leadership responsibilities.”
From 2008 to 2012, Francesco was an Analyst at Omega.
BIO,
Drug development,
Gene,
The,
Doctor of Philosophy,
Half-life,
Drug discovery,
Neoplasm,
Ligand,
Fusion,
Cancer,
Drug,
ART,
Bayer,
Patient,
Cell,
Ecosystem,
Regulatory affairs,
Biotechnology Innovation Organization,
Prostate cancer,
Pharmaceutical industry,
Medical imaging,
Bruland CAMBRIDGE, Mass. and OSLO, Norway and LONDON and BASEL, Switzerland, June 21, 2023 /PRNewswire/ -- ARTBIO, Inc. (ARTBIO), a clinical-stage radiopharmaceutical company developing a new class of targeted alpha radioligand therapies (ART), announced its founding with a $23 million seed financing led by F-Prime Capital with Omega Funds. ARTBIO was founded in 2021 by Roy Larsen, Øyvind Bruland, Radforsk, and F-Prime Capital to create highly targeted cancer therapies by pairing the optimal alpha-emitting isotope Pb212 with ligands against proven tumor-specific targets. ARTBIO is also creating an entirely new approach to ART manufacturing to overcome production and distribution challenges. In early 2022, Emanuele Ostuni, formerly Head of Europe for Cell and Gene Therapy at Novartis Oncology, joined ARTBIO as CEO to start building its world-class team and advance its proprietary technology, while securing additional funding from F-Prime Capital and Omega Funds.
Key Points:
- ARTBIO is also creating an entirely new approach to ART manufacturing to overcome production and distribution challenges.
- "Our unique approach combines Pb212 best in class properties with rationally designed ligands against tumor-specific targets to unlock the full therapeutic potential of alpha radioligand therapy," said Emanuele Ostuni, Ph.D., Chief Executive Officer of ARTBIO.
- Vicki Jardine, M.D., Ph.D., Vice President of Clinical Development; Former Senior Clinical Development Leader (Alpha Radioligand Therapies) at Bayer
Ted W. Love, M.D.
- "Roy and Øyvind are serial entrepreneurs responsible for developing the only alpha particle emitting radiopharmaceutical product currently on the market.
BIO,
Drug development,
Gene,
The,
Doctor of Philosophy,
Half-life,
Drug discovery,
Neoplasm,
Ligand,
Fusion,
Cancer,
Drug,
ART,
Bayer,
Patient,
Cell,
Ecosystem,
Regulatory affairs,
Biotechnology Innovation Organization,
Prostate cancer,
Pharmaceutical industry,
Medical imaging,
Bruland CAMBRIDGE, Mass. and OSLO, Norway and LONDON and BASEL, Switzerland, June 21, 2023 /PRNewswire/ -- ARTBIO, Inc. (ARTBIO), a clinical-stage radiopharmaceutical company developing a new class of targeted alpha radioligand therapies (ART), announced its founding with a $23 million seed financing led by F-Prime Capital with Omega Funds. ARTBIO was founded in 2021 by Roy Larsen, Øyvind Bruland, Radforsk, and F-Prime Capital to create highly targeted cancer therapies by pairing the optimal alpha-emitting isotope Pb212 with ligands against proven tumor-specific targets. ARTBIO is also creating an entirely new approach to ART manufacturing to overcome production and distribution challenges. In early 2022, Emanuele Ostuni, formerly Head of Europe for Cell and Gene Therapy at Novartis Oncology, joined ARTBIO as CEO to start building its world-class team and advance its proprietary technology, while securing additional funding from F-Prime Capital and Omega Funds.
Key Points:
- ARTBIO is also creating an entirely new approach to ART manufacturing to overcome production and distribution challenges.
- "Our unique approach combines Pb212 best in class properties with rationally designed ligands against tumor-specific targets to unlock the full therapeutic potential of alpha radioligand therapy," said Emanuele Ostuni, Ph.D., Chief Executive Officer of ARTBIO.
- Vicki Jardine, M.D., Ph.D., Vice President of Clinical Development; Former Senior Clinical Development Leader (Alpha Radioligand Therapies) at Bayer
Ted W. Love, M.D.
- "Roy and Øyvind are serial entrepreneurs responsible for developing the only alpha particle emitting radiopharmaceutical product currently on the market.
The Company,
TEL,
Stroke,
Kidney failure,
Medtech,
Risk,
Patient,
Hypertension,
Renal artery,
Axon Sports,
Physician,
Therapy,
Blood pressure,
Pharmaceutical industry,
Wiśniewski TEL AVIV, Israel, Jan. 9, 2023 /PRNewswire/ -- SoniVie Ltd. ("SoniVie" or the "Company"), a medical device company developing a proprietary solution to treat hypertension, announced today the completion of a $60 million series C round financing. The financing was led by Andera Partners, with participation from Supernova Invest and Omega Funds. Current SoniVie shareholder TechWald also participated.
Key Points:
- In conjunction with the financing, the Company appointed two renowned medtech experts to its Board of Directors, Raymond W. Cohen and Zeev Zehavi, as independent directors.
- The proceeds from SoniVie financing are envisioned to be used to reach clinical and regulatory milestones and to support TIVUS™ renal artery denervation program.
- Raphaël Wisniewski of Andera Partners commented, "SoniVie TIVUS™ has the potential to provide patients and physicians with a safe, efficient and easy to use device.
- We are thrilled to support this talented management together with our syndicate partners and our new board members".
The Company,
TEL,
Stroke,
Kidney failure,
Medtech,
Risk,
Patient,
Hypertension,
Renal artery,
Axon Sports,
Physician,
Therapy,
Blood pressure,
Pharmaceutical industry,
Wiśniewski TEL AVIV, Israel, Jan. 9, 2023 /PRNewswire/ -- SoniVie Ltd. ("SoniVie" or the "Company"), a medical device company developing a proprietary solution to treat hypertension, announced today the completion of a $60 million series C round financing. The financing was led by Andera Partners, with participation from Supernova Invest and Omega Funds. Current SoniVie shareholder TechWald also participated.
Key Points:
- In conjunction with the financing, the Company appointed two renowned medtech experts to its Board of Directors, Raymond W. Cohen and Zeev Zehavi, as independent directors.
- The proceeds from SoniVie financing are envisioned to be used to reach clinical and regulatory milestones and to support TIVUS™ renal artery denervation program.
- Raphaël Wisniewski of Andera Partners commented, "SoniVie TIVUS™ has the potential to provide patients and physicians with a safe, efficient and easy to use device.
- We are thrilled to support this talented management together with our syndicate partners and our new board members".
The Company,
TEL,
Stroke,
Kidney failure,
Medtech,
Risk,
Partner,
Patient,
Hypertension,
Renal artery,
Physician,
Therapy,
Blood pressure,
Pharmaceutical industry,
Wiśniewski,
Axon Sports TEL AVIV, ISRAEL, AND PARIS, FRANCE, JANUARY 10, 2023 -- SoniVie Ltd. ("SoniVie" or the "Company"), a medical device company developing a proprietary solution to treat hypertension, announced today the completion of a $60 million series C round financing. The financing was led by Andera Partners, with participation from Supernova Invest and Omega Funds. Current SoniVie shareholder TechWald also participated.
Key Points:
- Andera Partners invests in SoniVie, a medtech company developing a promising device for the treatment of hypertension
The issuer is solely responsible for the content of this announcement.
- The financing was led by Andera Partners, with participation from Supernova Invest and Omega Funds.
- Raphaël Wisniewski of Andera Partners commented, "SoniVie TIVUS™ has the potential to provide patients and physicians with a safe, efficient and easy to use device.
- We are thrilled to support this talented management together with our syndicate partners and our new board members".
Aerium,
Pantaleo,
Therapy,
Vaccination,
DRS,
Degenerative disease,
Medtech,
Leadership,
Multimedia,
Board,
Omega,
Health care,
Vaccine,
Volatile organic compound,
EPFL,
Research,
White,
Delta,
Capital,
Severe acute respiratory syndrome coronavirus 2,
Precision medicine,
CEO,
AstraZeneca,
Immunology,
Merck & Co.,
White House,
CHUV,
Omicron,
Technology,
Neutralizing antibody,
Virology,
COVID-19,
Trono,
Montreux Healthcare Fund,
Series,
BioRxiv,
Bill & Melinda Gates Foundation,
FDA,
Director,
History,
Partnership,
Antibody,
Financial services,
Management,
Pharmaceutical industry,
Medicine,
Takeda,
Coalition for Epidemic Preparedness Innovations,
Pfizer,
Ultragenyx,
Tropical Islands Resort,
Genetics While we are initially assisting populations vulnerable to COVID-19 in the prophylactic and therapeutic settings, our overall vision is to develop effective therapeutics against not just existing but also future epidemic and pandemic threats."
Key Points:
- While we are initially assisting populations vulnerable to COVID-19 in the prophylactic and therapeutic settings, our overall vision is to develop effective therapeutics against not just existing but also future epidemic and pandemic threats."
- Aerium Therapeutics has assembled a growing team of proven life science and enterprise leaders including:
CEO Rajeev Venkayya, M.D.
- Aerium Therapeutics is dedicated to epidemic and pandemic preparedness through the discovery and development of antibodies and small molecule antivirals against SARS-CoV-2 and other epidemic and pandemic threats.
- The company plans to expand its pipeline to antiviral therapeutics in late 2022 and will broaden its focus to other epidemic and pandemic threats in the future.
Retrieved on:
Thursday, October 14, 2021
Health,
Other Health,
Clinical Trials,
General Health,
Pharmaceutical,
Biotechnology,
Scripps Research,
The Programme,
Degenerative disease,
Disease,
POC,
Partner,
Gastrointestinal tract,
Therapy,
Medication,
Pharma,
EIF,
DVI,
Marshall Plan,
Precision medicine,
Health,
Patient,
ERP,
Biotechnology,
Computational biology,
Partner (business rank),
ABC,
BGV,
Drug discovery,
Alnylam Pharmaceuticals,
EUR,
Vertex Pharmaceuticals,
European Recovery Plan,
Liver,
Senior,
Socially responsible investing,
CBO,
Department,
PFM Group,
Eye,
Investment,
Executive,
Central nervous system,
Vertex,
CFTR,
Growth,
Atlas,
Atlas Venture,
EFSI,
LFA,
Cystic fibrosis,
Lists of diseases,
Institute of Liver and Biliary Sciences,
Company,
Omega,
Entrepreneurship,
United Nations Principles of Medical Ethics,
Pharmaceutical industry,
Management,
Aquaculture,
Fine chemical,
Rectify Pharmaceuticals, Inc. (“Rectify”),
Atlas Venture,
Omega Funds,
Forbion,
Longwood Fund,
RECTIFY PHARMACEUTICALS, INC. (“RECTIFY”),
ATLAS VENTURE,
OMEGA FUNDS,
FORBION,
LONGWOOD FUND Rectify Pharmaceuticals, Inc. , (Rectify) a biotechnology company developing Positive Functional Modulators (PFMs), disease-modifying therapeutics that restore ABC transporter function, today announced it has closed a $100 million Series A financing co-led by Atlas Venture, Omega Funds, Forbion, and Longwood Fund.
Key Points:
- Rectify Pharmaceuticals, Inc. , (Rectify) a biotechnology company developing Positive Functional Modulators (PFMs), disease-modifying therapeutics that restore ABC transporter function, today announced it has closed a $100 million Series A financing co-led by Atlas Venture, Omega Funds, Forbion, and Longwood Fund.
- Rectify plans to use this financing to fund the company through its first human proof-of-concept (POC) studies.
- We founded Rectify to deliver life-changing therapies to patients with serious genetic diseases, said Rajesh Devraj, Ph.D., President and Chief Executive Officer and venture partner with Atlas Venture.
- Jonathan Moore, Ph.D., Chief Scientific Officer, founded Rectify with Atlas Venture in 2020.
The oversubscribed financing was co-led by Omega Funds and TCG X.
Key Points:
- The oversubscribed financing was co-led by Omega Funds and TCG X.
- In connection with the close of the Series C financing, Michelle Doig, Partner, Head of Corporate Development, Omega Funds and Chen Yu, Founding Managing Partner, TCG X, will join Artios' Board of Directors.
- By investing in this financing round we are creating multiple avenues of value creation for our funds' investors."
- This financing follows an $84 million (65 million) Series B fundraise concluded in August 2018 and yields total capital raised to date from investors and strategic partners of more than US$320 million.
Biotechnology,
Health,
Pharmaceutical,
Clinical trials,
Oncology,
Biomarkers,
Biology,
Life sciences,
Biotechnology,
Chemical pathology,
KRAS,
Omega Funds,
Ikena Oncology Ikena Oncology, Inc. (Ikena), a clinical-stage biotechnology company that discovers and develops patient-directed, biomarker-driven cancer therapies, today announces the closing of $120 million in an oversubscribed Series B financing.
Key Points:
- Ikena Oncology, Inc. (Ikena), a clinical-stage biotechnology company that discovers and develops patient-directed, biomarker-driven cancer therapies, today announces the closing of $120 million in an oversubscribed Series B financing.
- Ikena intends to use the proceeds from this financing to advance its pipeline of targeted oncology therapies, including its novel development candidate TEAD inhibitor IK-930, and a new first-in-class preclinical program targeting KRAS signaling.
- In connection with this financing, Otello Stampacchia, Ph.D., Managing Director of Omega Funds, will join Ikenas Board of Directors.
- Omega Funds' portfolio companies have brought 37 products to market in multiple therapeutic areas, including oncology, rare diseases, precision medicine and others.
